CN118382643A - 一种包含抗FXI/FXIa抗体的药物组合物及其用途 - Google Patents

一种包含抗FXI/FXIa抗体的药物组合物及其用途 Download PDF

Info

Publication number
CN118382643A
CN118382643A CN202380015149.4A CN202380015149A CN118382643A CN 118382643 A CN118382643 A CN 118382643A CN 202380015149 A CN202380015149 A CN 202380015149A CN 118382643 A CN118382643 A CN 118382643A
Authority
CN
China
Prior art keywords
pharmaceutical composition
fxi
sucrose
histidine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380015149.4A
Other languages
English (en)
Chinese (zh)
Inventor
沈立君
赵志龙
李磊
汤辰翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Maijin Biomedical Technology Co ltd
Original Assignee
Shanghai Maijin Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Maijin Biomedical Technology Co ltd filed Critical Shanghai Maijin Biomedical Technology Co ltd
Publication of CN118382643A publication Critical patent/CN118382643A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202380015149.4A 2022-01-05 2023-01-05 一种包含抗FXI/FXIa抗体的药物组合物及其用途 Pending CN118382643A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210006206X 2022-01-05
CN202210006206 2022-01-05
CN2022100534412 2022-01-18
CN202210053441 2022-01-18
PCT/CN2023/070573 WO2023131213A1 (zh) 2022-01-05 2023-01-05 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN118382643A true CN118382643A (zh) 2024-07-23

Family

ID=87073189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380015149.4A Pending CN118382643A (zh) 2022-01-05 2023-01-05 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Country Status (6)

Country Link
US (1) US20250179213A1 (https=)
EP (1) EP4461749A4 (https=)
JP (1) JP2025502861A (https=)
CN (1) CN118382643A (https=)
TW (1) TW202333789A (https=)
WO (1) WO2023131213A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
EP3626266A4 (en) * 2017-05-16 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
PE20210462A1 (es) * 2018-07-05 2021-03-08 Bayer Ag METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
EP3898700A1 (en) * 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
KR20210151774A (ko) * 2019-04-16 2021-12-14 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-FXI/FXIa 항체 및 그 용도
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP4461749A1 (en) 2024-11-13
JP2025502861A (ja) 2025-01-28
TW202333789A (zh) 2023-09-01
US20250179213A1 (en) 2025-06-05
EP4461749A4 (en) 2025-03-26
WO2023131213A1 (zh) 2023-07-13

Similar Documents

Publication Publication Date Title
CN112512550B (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
CN110198739B (zh) 一种pd-l1抗体药物组合物及其用途
JP2026048838A (ja) 高濃度抗ｃ５抗体配合物
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
JP7807081B2 (ja) 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
CN109952093B (zh) 一种sost抗体药物组合物及其用途
CN115867316B (zh) 抗pd-1抗体药物组合物及其用途
CN111375059B (zh) 一种抗gitr抗体药物组合物及其用途
CN113507938A (zh) 包含抗il-5抗体的药物组合物及其用途
WO2020043095A1 (zh) 一种tim3抗体药物组合物及其用途
US20240352113A1 (en) Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
CN112839961A (zh) 一种cd40抗体药物组合物及其用途
CN118382643A (zh) 一种包含抗FXI/FXIa抗体的药物组合物及其用途
CN120051300A (zh) 一种抗masp2抗体的组合物及医药用途
HK40059623A (en) Pharmaceutical composition containing antibody against il-5 and use thereof
HK40045548A (en) TGF-β RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
HK40052110A (en) Cd40 antibody pharmaceutical composition and use thereof
HK40047597A (en) Anti-tim3 antibody pharmaceutical composition and use thereof
HK40025348A (en) Lag-3 antibody pharmaceutical composition and use thereof
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
HK40013346B (en) Pd-l1 antibody pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114173

Country of ref document: HK